Showing results (11-20 of 67) with videos related to
Sort By:
Pageof 7
Mayo Clinic Proceedings|October 6, 2015
Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015Philip A Thompson, Hagop M Kantarjian, Jorge E CortesHistopathology|June 22, 2012
Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centrePenelope A McKelvie, Philip A Thompson, Constantine S TamFuture Oncology (London, England)|February 17, 2015
Shifting paradigms in the treatment of chronic lymphocytic leukemiaPhilip A Thompson, Elizabeth J Shpall, Michael J KeatingBlood|April 10, 2025
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemiaBrian T Grainger, Philip A Thompson, Chan Y CheahBlood Advances|March 17, 2026
Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effectiveMathias Castonguay, Mary Ann Anderson, Philip A Thompson, et al.Transfusion|January 14, 2014
Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumorsPhilip A Thompson, Deborah May, Peter F Choong, et al.Blood Advances|January 25, 2023
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignanciesKelly S Chien, Christine B Peterson, Elliana Young, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 20, 2014
Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantationPhilip A Thompson, Andrew Lim, Yvonne Panek-Hudson, et al.Leukemia & Lymphoma|June 15, 2023
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulationLaura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, et al.Cancer|May 17, 2016
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicityPhilip A Thompson, Francesco Stingo, Michael J Keating, et al.Pageof 7